Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2016-02-12 Interim / Quarterly Rep…
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report H1 2016
2016-02-12 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'CURRENT REPORT' and dated January 8, 2016. It reports on the adjournment of a special shareholders meeting due to lack of quorum. The content is an announcement of a corporate event rather than a full financial report or detailed management discussion. The document length is 2384 characters, which is relatively short and contains no financial statements or detailed analysis. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory filing reporting a specific event, so it best fits the 'Regulatory Filings' (RNS) category as a general announcement that does not fit other specific categories.
2016-01-08 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2015-12-01 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2016
2015-11-13 English
TRANSITION REPORT
Annual Report Classification · 100% confidence The document is titled "FORM 10-K" and is filed with the U.S. Securities and Exchange Commission (SEC). It is explicitly identified as a "transition report under section 13 or 15(d) of the securities exchange act of 1934" for the transition period from January 1, 2015 to June 30, 2015. The content includes detailed sections typical of an annual report such as Business Overview, Risk Factors, Legal Proceedings, Management’s Discussion and Analysis, Financial Statements, and Executive Compensation. The length of the document (15,000 characters) and the detailed financial and business information confirm it is the full report, not just an announcement or certification. Therefore, this document is a full Annual Report on Form 10-K, specifically a transition 10-K report.
2015-09-30 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically reports a change in the company's fiscal year end from December 31 to June 30. It mentions that the company will next file its Annual Report on Form 10-K covering the transition period. The document is short (2406 characters) and serves as an announcement of a corporate event rather than a full financial report or detailed filing. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2015-07-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.